自噬在慢性肾脏病（chronic kidney disease，CKD）的发生发展中发挥着重要的作用，脂代谢紊乱是慢性肾脏病发生发展的重要因素之一，在心血管疾病中，自噬与脂代谢紊乱密切相关，在CKD中，两者关系尚未明确。我们前期研究显示益肾清利活血组方具有较好的治疗CKD的作用，其作用机制可能与AMPK对自噬的调节有关。因此，本项目利用脂代谢紊乱导致的肾损伤体内外模型，明确自噬在脂代谢紊乱肾损伤中的作用，阐明益肾清利活血组方通过调控自噬治疗CKD的作用与机理，同时检测肾病综合征不同病理类型患者血清软脂酸水平，分析脂代谢紊乱特点，研究其与尿蛋白水平、肾功能、心血管事件的关系。通过本项目，将明确益肾清利活血法通过调控自噬改善脂代谢紊乱治疗肾脏病的作用和机理，为CKD的治疗提供新的靶点与中医药治疗手段，为治疗CKD提供新策略。

Autophagy plays an important role in the development of chronic kidney disease(CKD).Lipometabolic disturbance is known as one of the progressive risk factors of CKD .Our previous studies demonstrated that tonifying kidney-clearing- activating blood therapy(TKCABT) can retard progression of CKD. The regulation of AMPK on autophagy is possibly underlying the protection of TKCABT. So we hypothesis that TKCABT improve hyperlipomia-induced renal injury via regulation of autophagy. In this study, renal tubular epithelial cell line will be involved to investigate the regulatory role of autophagy and the protection of TKCABT in palmitic acid-induced cell damage in vitro. In vivo, high fat diet- and palmitic acid intravenous injection-induced hyperlipomia-elicited kidney injury model in SD rat are established respectively. The sample of serum, urine, and kidney tissue will be collected to evaluate the effectiveness of TKCABT and role of autophagy in kidney damage. Patients with hyperlipomia in NS will be enrolled, the serum level of palmitic acid will be detected to analyze the association with progression of CKD and cardiovascular event. In general, we will clarify the therapeutic mechanism of TKCABT and provide novel target for the treatment of CKD.